SABS today
$3.11+$0.04 (+1.30%)close Nov 11, 2026Trend
DailyUptrend (starting)
4 hourStrong Bullish
1 hourStrong Bullish
15 minSymmetric Triangle
5 minSymmetric Triangle
Daily trend turns down below $2.45
Key levels
Resistance$3.40
Resistance$3.16
Support$2.91
Support$2.45
Latest news & SEC filings
EarningsSAB Biotherapeutics Posts Third-Quarter 2026 Numbers
EarningsSAB Biotherapeutics posts smaller quarterly loss than expected
All SABS news →About SAB Biotherapeutics
SAB Biotherapeutics is a clinical-stage biopharmaceutical company that develops human antibody-based treatments for conditions in which the body's defenses attack its own tissues. Its main candidate, SAB-142, is a human anti-thymocyte globulin being tested for type 1 diabetes. The company produces these antibodies using genetically modified cattle rather than relying on donated human blood. It is based in the United States and runs clinical studies across several countries.
Based on the company's 10-K filed Mar 9, 2026.
Nasdaq · Healthcare
SAB Biotherapeutics, Inc. (SABS)
What Is the Price Target for SABS?
SEPT Low Target
$10.00
SEPT Mid Target
$11.50
SEPT High Target
$16.00
Analyst Consensus
$11.50
Is SABS a Buy or Sell Right Now?
Thesis
- •Revenue growing -40.9% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for SABS.
Start Free Trial →Is SABS Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
PEG, Analyst Consensus
Fair Value
$0.24
27
Moat Score
NONE
4/9
Piotroski Score
4.2
Altman Z-Score
What Is Smart Money Doing with SABS?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Kropotova Alexandra | officer | Sale | 473 | - | Sep 17, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →SABS Growth Story
Revenue YoY
-40.9%
3yr Revenue CAGR
-72.1%
EPS Growth YoY
78.53%
FCF Growth YoY
-32.0%
Revenue Trend
ACCELERATING
Dark Pool Trades for SABS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for SABS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:53:55 | $3.10 | 2,800 | $$9K | BUY |
| 20:45:49 | $3.08 | 1,100 | $$3K | SELL |
| 20:34:32 | $3.10 | 2,500 | $$8K | BUY |
| 20:33:51 | $3.10 | 2,000 | $$6K | BUY |
| 19:28:26 | $3.07 | 12,754 | $$39K | SELL |
5 dark pool trades shown · $$65K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for SAB Biotherapeutics, Inc. (SABS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →SABS — frequently asked questions
What is SABS stock price today?
SAB Biotherapeutics, Inc. (SABS) is at $3.11, up 1.30% (+$0.04) at the Nov 11, 2026 close.
Why is SABS stock moving today?
Latest SABS news — Nov 5, 2026: SAB Biotherapeutics Posts Third-Quarter 2026 Numbers · Nov 5, 2026: SAB Biotherapeutics posts smaller quarterly loss than expected
What is the SABS price target?
The average analyst price target for SABS is $11.50, ranging from $10 to $16, based on 6 analysts. Latest: Barclays initiates on Jun 24, 2026.
What do analysts rate SABS?
Analyst ratings for SABS: 0 Buy, 7 Hold, 0 Sell — consensus Hold.
Did SABS beat earnings?
SABS last reported on Aug 6, 2026: EPS -$0.28 vs -$0.28 expected — a beat of 1.1%.
What is SABS's P/E ratio?
SABS trades at a P/E of 13.8 vs a Healthcare average of 18.5.
Does SABS pay a dividend?
SABS does not currently pay a dividend.
What are SABS support and resistance levels?
Support: $2.91, $2.45, $2.10. Resistance: $3.16, $3.40, $3.79.
What are insiders doing with SABS?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on SABS?
Nov 5, 2026: SAB Biotherapeutics Posts Third-Quarter 2026 Numbers · Nov 5, 2026: SAB Biotherapeutics posts smaller quarterly loss than expected